NCT05749432View on ClinicalTrials.gov

A Phase I Study of Hemay181 in Patients With Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

March 20, 2023

Primary Completion Date

January 31, 2026

Study Completion Date

July 31, 2026

Conditions
Solid Tumor
Interventions
DRUG

Hemay181

Hemay181 will be given intravenously on the first day per cycle, and the treatment cycle is 21-days.

Trial Locations (1)

Unknown

RECRUITING

Beijing Cancer Hospital, Beijing

Sponsors
All Listed Sponsors
lead

Ganzhou Hemay Pharmaceutical Co., Ltd

INDUSTRY

NCT05749432 - A Phase I Study of Hemay181 in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter